This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, W.-S. Articles by Marks, P. A. Search for Related Content PubMed PubMed Citation Articles by Xu, W.-S. Articles by Marks, P. A.

Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Paul A. Marks, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-6568; Fax: 212-639-2861; E-mail: paula_marks{at}mskcc.org.

Histone deacetylase (HDAC) inhibitors can induce various transformed cells to undergo growth arrest and/or death. Suberoylanilide hydroxamic acid (SAHA) is an HDAC inhibitor which is in phase I/II clinical trials and has shown antitumor activity in hematologic and solid tumors at doses well tolerated by patients. HDAC is the target for SAHA, but the mechanisms of the consequent induced death of transformed cells are not completely understood. In this study, we report that SAHA induced polyploidy in human colon cancer cell line HCT116 and human breast cancer cell lines, MCF-7, MDA-MB-231, and MBA-MD-468, but not in normal human embryonic fibroblast SW-38 and normal mouse embryonic fibroblasts. The polyploid cells lost the capacity for proliferation and committed to senescence. The induction of polyploidy was more marked in HCT116 p21^WAF1–/– or HCT116 p53–/– cells than in wild-type HCT116. The development of senescence of SAHA-induced polyploidy cells was similar in all colon cell lines. The present findings indicate that the HDAC inhibitor could exert antitumor effects by inducing polyploidy, and this effect is more marked in transformed cells with nonfunctioning p21^WAF1 or p53 genes.

This article has been cited by other articles:

				W. Weichert, A. Roske, S. Niesporek, A. Noske, A.-C. Buckendahl, M. Dietel, V. Gekeler, M. Boehm, T. Beckers, and C. Denkert Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo Clin. Cancer Res., March 15, 2008; 14(6): 1669 - 1677. [Abstract] [Full Text] [PDF]

				S. Vernarecci, P. Ornaghi, A. Bagu, E. Cundari, P. Ballario, and P. Filetici Gcn5p Plays an Important Role in Centromere Kinetochore Function in Budding Yeast Mol. Cell. Biol., February 1, 2008; 28(3): 988 - 996. [Abstract] [Full Text] [PDF]

				L. Magnaghi-Jaulin, G. Eot-Houllier, G. Fulcrand, and C. Jaulin Histone Deacetylase Inhibitors Induce Premature Sister Chromatid Separation and Override the Mitotic Spindle Assembly Checkpoint Cancer Res., July 1, 2007; 67(13): 6360 - 6367. [Abstract] [Full Text] [PDF]

				S. Senese, K. Zaragoza, S. Minardi, I. Muradore, S. Ronzoni, A. Passafaro, L. Bernard, G. F. Draetta, M. Alcalay, C. Seiser, et al. Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation Mol. Cell. Biol., July 1, 2007; 27(13): 4784 - 4795. [Abstract] [Full Text] [PDF]

				J. S. Carew, S. T. Nawrocki, C. N. Kahue, H. Zhang, C. Yang, L. Chung, J. A. Houghton, P. Huang, F. J. Giles, and J. L. Cleveland Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood, July 1, 2007; 110(1): 313 - 322. [Abstract] [Full Text] [PDF]

				G. Egger, A. M. Aparicio, S. G. Escobar, and P. A. Jones Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2'-Deoxycytidine Treatment Cancer Res., January 1, 2007; 67(1): 346 - 353. [Abstract] [Full Text] [PDF]

				Y. Liu, C. E. Denlinger, B. K. Rundall, P. W. Smith, and D. R. Jones Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65 J. Biol. Chem., October 20, 2006; 281(42): 31359 - 31368. [Abstract] [Full Text] [PDF]

				K. Bhalla Overview and Cytoplasmic Targets of HDAC Inhibitors Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 309 - 312. [Full Text] [PDF]

				R. W. Johnstone The Intrinsic and Extrinsic Apoptotic Pathways in HDAC Inhibitor Lethality Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 313 - 317. [Full Text] [PDF]